C. pneumoniae and possible mechanisms of coronary artery disease

Introduction

The case for a causal role of C. pneumoniae in coronary artery disease would be greatly strengthened if plausible molecular or cellular mechanisms involving known risk factors could be identified. This section reviews the evidence for some of the suggested mechanisms by which C. pneumoniae might cause coronary artery disease.

Mechanisms

[Caveat emptor: The following takes a set of individual experimental observations and puts them together, out of context, to show that there are plausible mechanisms by which C. pneumoniae might exacerbate heart disease. Some of the foundations on which this "construction" is based, for example the role of chlamydial heat shock protein in chronic disease, are tenets of chlamydial faith rather than certainties. Likewise it is likely that other bacteria also have a role. At the end of the day, the crucial test is not the beauty of the potential mechanisms, insightful though they may be, but whether it is possible to demonstrate significant benefits to public health by the targeted use of antibiotic for coronary artery disease].

  • Portal of entry. [See: C. pneumoniae pneumonia]. As already reviewed, C. pneumoniae is a common agent of lower respiratory tract infection, involving the alveolar air sacs where it is likely to be ingested by alveolar macrophages. Access from the lung to the circulation is relatively easy as only a single cell separates the alveolar air sac from the circulation. C. pneumoniae may be transported across the cellular barrier either as free particles or, more likely, carried within macrophages which are actively migrating across the endothelium . Chlamydial replication in matured human macrophages is probably limited [Airenne et al., 1998] but the organism might be transferred to CD3+ T lymphocytes during antigen processing.

  • Dissemination in the blood. A major study of 1300 patients demonstrated that C. pneumoniae circulates in the blood stream within mononuclear cells [Wong et al., 1999], subsequently identified as CD3+ T lymphocytes [Kaul et al., 2000].

  • Adhesion to vessel walls and entry. In coronary artery disease, C. pneumoniae is associated with monocytes potentially capable of adherence to vessel walls. This is uncommon in normal blood donors [Kaul et al., 2000]. C. pneumoniae infected monocytes show enhanced adhesion to aortic endothelial cells [Kalayoglu et al., 2001]. At sites of active atheroma , inflammatory cytokines, and chlamydial infection of endothelia will lead to the upregulation of vascular adhesion factors, including E-selectin, ICAM-1, and VCAM-1 [Kaukoranta-Tolvanen et al., 1996a; see also Cytokine Induction].

  • Infection and dysfunction of endothelial cells. Monocyte cell lines can transmit C. pneumoniae infection to coronary artery endothelial cells in cell culture [Gaydos, 2000]. Indeed, C. pneumoniae is capable of infecting all the cell types typically associated with atheroma, including aortic artery smooth muscle cells [Gaydos et al., 1996; Godzik et al., 1995; Kaukoranta-Tolvanen et al., 1996b]. C. pneumoniae infection of endothelia impairs the latter's ability to induce nitric oxide-mediated arterial relaxation [Liuba et al., 2000] perhaps by inducing cyclooxygenase-dependent vaso-constrictors. Endothelial dysfunction is observed in both resistance and epicardial coronary vessels [Liuba et al., 2003]. C. pneumoniae infection of endothelia also promotes the transendothelial migration of inflammatory cells [Molestina et al., 1999], the production of inflammatory mediators [Summersgill et al., 2000] and induction of pro-coagulant activity [Fryer et al., 1997] and of platelet derived growth factor B [Coombes et al., 2002].

  • Proliferation of smooth muscle cells and thickening of the aortic intima characteristic of atheroma may be stimulated in part by C. pneumoniae-triggered production of platelet derived growth factor B [Coombes et al., 2002].

  • Atherogenesis. Atheroma is increasingly recognised as involving inflammatory stimuli. There is considerable evidence that atherogenesis is partly driven by inflammatory stimuli, notably the pro-inflammatory cytokines. Chlamydiae are capable of interacting with macrophages or epithelia to generate a variety of pro-inflammatory cytokines [see: Cytokine Induction]. Two other key events in atherogenesis are: 1) the transformation of macrophages into fat-laden foam cells as a result of the uptake of low density lipoproteins (LDL) via the classic Apo B/E receptor, resulting in the accumulation of cholesteryl esters and; 2) the oxidation of lipoproteins at the site of lesion development, resulting in tissue damage. Normally macrophages do not take up exogenous LDL to an excessive extent because the Apo B/E receptor is rapidly down regulated by the intracellular accumulation of cholesteryl esters derived from the internalised LDL. However, C. pneumoniae-infected human or mouse macrophages accumulate LDL resulting in their transformation into cholesterol-laden foam cells [Kalayoglu & Byrne 1998b]. This process does not required the prior oxidation of LDL before uptake, since it occurs in the presence of anti-oxidants, and it involves an unknown mechanism independent of the classic Apo B/E receptor since it occurs in LDL-receptor-deficient, knock out mice [Kalayoglu et al., 2000]. The precise mechanism of chlamydial-induced LDL uptake remains to be determined. It may involve chlamydial modification of LDL prior to uptake, participation of an unknown receptor and / or interference with the normal macrophage cholesterol ester pump out mechanisms, such as that, in Tangier disease, involving the ATP-binding cassette transporter 1 (ABC1) [Rust et al., 1999]. Chlamydiae in any case interfere with the normal intracellular trafficking of lipid and membranes within cells [see: Membrane Traffic]. Chlamydial LPS is thought to be a major trigger of chlamydial-induced LDL uptake [Kalayoglu & Byrne, 1998a]. For a useful review see Kalayoglu et al., 2002.

  • Cell mediated immune responses to chlamydial heat shock protein in plaque. Chsp60 has been identified within human atheromatous tissue and in aortic valve stenosis [Skowasch et al., 2003], is both immunogenic and pro-inflammatory and is thought to be associated with the immunopathology of chlamydial disease [Kalayoglu et al., 2000 see: Heat Shock Proteins] including the gamma interferon-induced production of IFNg. Chsp60 can activate the cellular immune response through the CD14 monocyte receptor for bacterial lipopolysaccharide [Kol et al., 2000]. Chsp60 promotes matrix metalloproteinase and cytokine production by monocytes. It also promotes cytokine production by endothelial cells and smooth muscle cells. Thus chsp60 may function both as a direct antigenic and inflammatory stimulant and as a transducer of unknown cellular signalling systems leading to cellular activation within the atheromatous plaque [Kalayoglu et al., 2000]. Chlamydial heat shock protein [chsp60] also induced monocyte LDL oxidation in a dose dependent manner, whereas another chlamydial heat shock protein, chsp10, did not [Kalayoglu et al., 1999a; 2000].

  • Plaque rupture. Chlamydial induced activation of matrix metalloproteases among other factors [Kol et al., 1998] may lead to plaque destabilisation and premature rupture. This in turn may give rise to myocardial infarction. At present there is very little experimental evidence for this other than the observed but probably confounded association of C. pneumoniae antibody with myocardial infarction [see: C. pneumoniae serological evidence].

[MEW] August 2003.

NEXT: CAD antibiotic trials in humans

References

Airenne, S., Surcel, H. M., Alakarppa, H., Laitinene, K., Saikku, P. & Laurila, A. (1998). Characterization of Chlamydia pneumoniae infection in human monocytes, pp 123 - 126 In: Stephens, R. S. et al., eds., Chlamydial infections. Proceedings of the ninth international symposium on human chlamydial infections. International Chlamydia Symposium, San Francisco.

Byrne, G. I. & Kalayoglu, M.V. (1999). Chlamydia pneumoniae and atherosclerosis: links to the disease process. American Heart Journal 138, S488 - 490.

Byrne, G. I., Skarlotos, S. I., Grunfeld, C., Kalayoglu, M. V., Libby, P., Saikku, P., Summersgill, J. T. & Wyrick, P. (2000). Collaborative multidisciplinary workshop report: interface of lipid metabolism, atherosclerosis, and Chlamydia infection.

Caligiuri, G., Rottenberg, M., Nicoletti, A., Wigzell, H. & Hansson, G. K. (2001). Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation 103, 2834 - 2038.

Coombes, B. K., Chiu, B., Fong, I. W. & Mahony, J. B. (2002). Chlamydia pneumoniae infection of endothelial cells induces transcriptional activation of platelet-derived growth factor-B: a potential link to intimal thickening in a rabbit model of atherosclerosis. Journal of Infectious Diseases 185, 1621 - 1630.

Coombes, B. K. & Mahony, J. B. (1999). Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s). Infection and Immunity 67, 2909 - 2915.

Fryer, R. H., Schwobe, E. P., Woods, M. L. & Rodgers, G. M. (1997). Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. Journal of Investigative Medicine 45, 168 - 174.

Gaydos, C. A. (2000). Growth in vascular cells and cytokine production by Chlamydia pneumoniae. Journal of Infectious Disease 181 Supplement 3, S473 - 478.

Godzik, K. L., O'Brien, E. R., Wang, S. K. & Kuo, C. C. (1995). In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. Journal of Clinical Microbiology 33, 2411 - 2414. Full article [Acrobat]

Kalayoglu M. V. & Byrne, G. I. (1998a). A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infection and Immunity 66, 5067 - 5072. Full article [Acrobat]

Kalayoglu M. V. & Byrne, G. I. (1998b). Induction of macrophage foam cell formation by Chlamydia pneumoniae. Journal of Infectious Diseases 177, 725 - 729.

Kalayoglu, M. V., Hoerneman, B., LaVerda, D., Morrison, S. G., Morrison, R. P. & Byrne, G. I. (1999a). Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. Journal of Infectious Diseases 180, 780 - 790.

Kalayoglu, M. V., Indrawati, Morrison, R. P., Morrison, S. G., Yuan, Y. & Byrne, G. I. (2000). Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. Journal of Infectious Diseases 181, Suppl 3: S483 - 489.

Kalayoglu, M. V., Libby, P. & Byrne, G. I. (2002). Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA. 288, 2724 - 2731. Full article [Acrobat]

Kalayoglu, M. V., Miranpuri, G. S., Golenbock, D. T. & Byrne, G. I. (1999b). Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae. Microbes and Infection 1, 409 - 418.

Kalayoglu, M. V., Perkins, B. N. & Byrne, G. I. (2001). Chlamydia pneumoniae-infected monocytes exhibit increased adherence to human aortic endothelial cells. Microbes and Infection 3, 963 - 969.

Kaukoranta-Tolvanen, S. S., Ronni, T., Leinonen, M., Saikku, P. & Laitinen, K. (1996a). Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. Microbial Pathogenesis 21, 407 - 411.

*Kaukoranta-Tolvanen, S. S., Teppo, A. M., Laitinen, K., Saikku, P., Linnavuori, K. & Leinonen, M. (1996b). Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microbial Pathogenesis 21, 215 - 221.

Kaul, R., Uphoff, J., Wiedeman, J., Yadlapalli, S. & Wenman, W. M. (2000). Detection of Chlamydia pneumoniae DNA in CD3+ lymphocytes from healthy blood donors and patients with coronary artery disease. Circulation 102, 2341 - 2346. Full article [Acrobat]

Kol, A., Sukhova, G. K., Lichtman, A. H. & Libby, P. (1998). Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 98, 300 - 307. Full article [Acrobat]

Kol, A., Lichtman, A. H., Finberg, R. W., Libby, P. & Kurt-Jones, E. A. (2000). Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. Journal of Immunology 164, 13 - 17. Full article [Acrobat]

Liuba, P., Karnani, P., Pesonen, E., Paakkari, I., Forslid, A., Johansson, L., Persson, K., Wadstrom, T. & Laurini, R. (2000). Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein E-knockout mice. Circulation 102, 1039 - 1044. Full article [Acrobat]

Liuba, P., Pesonen, E., Paakkari, I., Batra, S., Forslid, A., Kovanen, P., Pentikainen, M., Persson, K. & Sandstrom, S. (2003). Acute Chlamydia pneumoniae infection causes coronary endothelial dysfunction in pigs. Atherosclerosis 167, 215 - 222. Full article [Acrobat]

Maass, M., Jahn, J., Gieffers, J., Dalhoff, K., Katus, H. A. & Solbach, W. (2000). Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction. Journal of Infectious Disease 181 Suppl 3, S449 - 451.

Moazed, T. C., Campbell, L. A., Rosenfeld, M. E., Grayston, J. T. & Kuo, C. C. (1999). Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Journal of Infectious Diseases 180, 238 - 241.

Molestina, R. E., Miller, R. D., Ramirez, J. A. & Summersgill, J. T. (1999). Infection of human endothelial cells with Chlamydia pneumoniae stimulates transendothelial migration of neutrophils and monocytes. Infection and Immunity 67, 1323 - 1330. Full article [Acrobat]

Rust, S., Rosier, M., Funke, H. et al. (1999). Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nature Genetics 22, 352 - 355.

Skowasch, D., Yeghiazaryan, K., Schrempf, S., Golubnitschaja, O., Welsch, U., Preusse, C. J., Likungu, J. A., Welz, A., Luderitz, B. & Bauriedel, G. (2003). Persistence of Chlamydia pneumoniae in degenerative aortic valve stenosis indicated by heat shock protein 60 homologues. Journal of Heart Valve Disease 12, 68 - 75.

Summersgill, J. T., Molestina, R. E., Miller, R. D. & Ramirez, J. A. (2000). Interactions of Chlamydia pneumoniae with human endothelial cells. Journal of Infectious Disease 181 Suppl 3., S479 - 482.

Wong, Y. K., Dawkins, K. D. & Ward, M. E. (1999a). Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease. Journal of the American College of Cardiology 34, 1435 - 1439. [Large study on 1300 patients indicating that the presence of circulating C. pneumoniae DNA in peripheral blood mononuclear cells was associated with greater risk of angiographic abnormalities in males]

Registered users: Please add any comments below.

 
Topic revision: r12 - 2011-04-11 - SanderO
 
This site is powered by the TWiki collaboration platformCopyright © 2008-2014 by the contributing authors. All material on this collaboration platform is the property of the contributing authors.
Ideas, requests, problems regarding TWiki? Send feedback